OCUL Quote, Financials, Valuation and Earnings

Candel Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of --. Ocular Therapeutix's return on equity of -56.05% beat Candel Therapeutics's return on equity of --.

Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 57.44%. On the other hand Candel Therapeutics has an analysts' consensus of $21.00 which suggests that it could grow by 203.47%. Given that Candel Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Candel Therapeutics is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Candel Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Candel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Candel Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Candel Therapeutics quarterly revenues of --. Ocular Therapeutix's net income of -$64.1M is lower than Candel Therapeutics's net income of $7.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Candel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 31.97x versus 2,124.14x for Candel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -1366.49%. Ocular Therapeutix's return on equity of -56.05% beat Recursion Pharmaceuticals's return on equity of -82.61%.

Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 57.44%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.14 which suggests that it could grow by 29.4%. Given that Ocular Therapeutix has higher upside potential than Recursion Pharmaceuticals, analysts believe Ocular Therapeutix is more attractive than Recursion Pharmaceuticals.

Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Ocular Therapeutix's net income of -$64.1M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 31.97x versus 29.16x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -271.3%. Ocular Therapeutix's return on equity of -56.05% beat Spero Therapeutics's return on equity of -108.26%.

Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 57.44%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 101.61%. Given that Spero Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Spero Therapeutics is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Ocular Therapeutix's net income of -$64.1M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 31.97x versus 4.78x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of 4.19%. Ocular Therapeutix's return on equity of -56.05% beat TG Therapeutics's return on equity of 19.78%.

Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 57.44%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 3.34%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ocular Therapeutix's net income of -$64.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 163.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 31.97x versus 16.31x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.